Renal transplantation in young children. 1995

C P Burren, and C L Jones, and D M Francis, and H R Powell, and R G Walker
Department of Paediatrics, University of Melbourne, Royal Children's Hospital, Vic.

OBJECTIVE To review the outcome of renal transplantation in small children treated with triple immunosuppression at a single Australian centre. METHODS The medical records of all children under the age of five years undergoing renal transplantation from 1988 were reviewed. The duration of follow-up was 30 months (range 18-36). RESULTS Six children received seven renal allografts (five living-related [LR] and two cadaveric [CD]). They had a median age of 3.75 years (range 1.5-4.9) and weight of 11.6 kg (9.1-14.5) at the time of transplantation. All patients received an immunosuppressive regime involving cyclosporin A, azathioprine and prednisolone. There were no deaths. The only graft lost was a CD graft (severe acute rejection within one week of transplantation). Hypertension occurred in all recipients and usually required more than one antihypertensive drug for treatment. Renal function measured by serum median creatinine concentration (range) was 0.05 mmol/L (0.03-0.11) at three months (n = 6) and 0.10 mmol/L (0.07-0.22) at 30 months (n = 4). Growth estimated from median (range) height standard deviation scores was -1.97 (-1.36-(-4.04)) at three months (n = 6) and -1.90 (-1.74-2.50) at 30 months (n = 4). No patient was entirely weaned from prednisolone. Cyclosporin A side effects included hirsutism (five patients), gingival hyperplasia (six patients) and nephrotoxicity (three patients). CONCLUSIONS Satisfactory patient and graft survival can be accomplished in this recipient age group. The results compare with other international experience and accumulating Australian experience. Hypertension and poor skeletal growth were consistent observations. The long-term outcome of renal function using triple immunosuppression remains to be determined.

UI MeSH Term Description Entries
D007165 Immunosuppression Therapy Deliberate prevention or diminution of the host's immune response. It may be nonspecific as in the administration of immunosuppressive agents (drugs or radiation) or by lymphocyte depletion or may be specific as in desensitization or the simultaneous administration of antigen and immunosuppressive drugs. Antirejection Therapy,Immunosuppression,Immunosuppressive Therapy,Anti-Rejection Therapy,Therapy, Anti-Rejection,Therapy, Antirejection,Anti Rejection Therapy,Anti-Rejection Therapies,Antirejection Therapies,Immunosuppression Therapies,Immunosuppressions,Immunosuppressive Therapies,Therapies, Immunosuppression,Therapies, Immunosuppressive,Therapy, Immunosuppression,Therapy, Immunosuppressive
D007223 Infant A child between 1 and 23 months of age. Infants
D008297 Male Males
D011183 Postoperative Complications Pathologic processes that affect patients after a surgical procedure. They may or may not be related to the disease for which the surgery was done, and they may or may not be direct results of the surgery. Complication, Postoperative,Complications, Postoperative,Postoperative Complication
D011239 Prednisolone A glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. Di-Adreson-F,Predate,Predonine,Di Adreson F,DiAdresonF
D002675 Child, Preschool A child between the ages of 2 and 5. Children, Preschool,Preschool Child,Preschool Children
D004359 Drug Therapy, Combination Therapy with two or more separate preparations given for a combined effect. Combination Chemotherapy,Polychemotherapy,Chemotherapy, Combination,Combination Drug Therapy,Drug Polytherapy,Therapy, Combination Drug,Chemotherapies, Combination,Combination Chemotherapies,Combination Drug Therapies,Drug Polytherapies,Drug Therapies, Combination,Polychemotherapies,Polytherapies, Drug,Polytherapy, Drug,Therapies, Combination Drug
D005260 Female Females
D005500 Follow-Up Studies Studies in which individuals or populations are followed to assess the outcome of exposures, procedures, or effects of a characteristic, e.g., occurrence of disease. Followup Studies,Follow Up Studies,Follow-Up Study,Followup Study,Studies, Follow-Up,Studies, Followup,Study, Follow-Up,Study, Followup
D006085 Graft Survival The survival of a graft in a host, the factors responsible for the survival and the changes occurring within the graft during growth in the host. Graft Survivals,Survival, Graft,Survivals, Graft

Related Publications

C P Burren, and C L Jones, and D M Francis, and H R Powell, and R G Walker
May 1973, American journal of surgery,
C P Burren, and C L Jones, and D M Francis, and H R Powell, and R G Walker
September 1995, The Australian and New Zealand journal of surgery,
C P Burren, and C L Jones, and D M Francis, and H R Powell, and R G Walker
June 1975, Urology,
C P Burren, and C L Jones, and D M Francis, and H R Powell, and R G Walker
August 1982, Lancet (London, England),
C P Burren, and C L Jones, and D M Francis, and H R Powell, and R G Walker
February 1983, Lancet (London, England),
C P Burren, and C L Jones, and D M Francis, and H R Powell, and R G Walker
October 1990, Pediatrics,
C P Burren, and C L Jones, and D M Francis, and H R Powell, and R G Walker
February 1989, Transplantation proceedings,
C P Burren, and C L Jones, and D M Francis, and H R Powell, and R G Walker
June 1994, Pediatric nephrology (Berlin, Germany),
C P Burren, and C L Jones, and D M Francis, and H R Powell, and R G Walker
March 1993, The Journal of urology,
C P Burren, and C L Jones, and D M Francis, and H R Powell, and R G Walker
February 2009, Pediatrics international : official journal of the Japan Pediatric Society,
Copied contents to your clipboard!